Supplemental Reading List: Cannabis As Medicine

Abrahamov A, Abrahamov A, and Mechoulam R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci . 1995;56(23-24):2097-102. doi: 10.1016/0024-3205(95)00194-b. https://pubmed.ncbi.nlm.nih.gov/7776837/

Abuhasira R, Schleider LBL, Mechoulam R, Novack V. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine, Volume 49, Pages 44–50. https://pubmed.ncbi.nlm.nih.gov/29398248/

Adams J, Hunt M, and Clark, JH (1940) Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. Journal of the American Chemical Society. 62 (1), 196-200. https://pubs.acs.org/doi/10.1021/ja01858a058

Adams R, Wolff H, Cain CK, Clark JH (1940) Structure of cannabidiol. V. Position of the alicyclic double bonds. J Am Chem Soc 62: 2215–2219. https://pubs.acs.org/doi/abs/10.1021/ja01865a085

Aggarwal, Carter, Sullivan, Zumbrunnen, Morrill, and Mayer. (2012). Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington state reveals managed chronic illness and debility. American Journal of Hospice & Palliative Medicine, 30(6), 523-531. https://journals.sagepub.com/doi/10.1177/1049909112454215

Aggarwal, SK. (2013) Cannabinergic pain medicine: A concise clinical primer and survey of randomized-controlled trial results. The Clinical Journal of Pain. https://pubmed.ncbi.nlm.nih.gov/22367503/

Aso, E, Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol. 2014; 5: 37. https://pubmed.ncbi.nlm.nih.gov/24634659/

Avraham Y, Ben-Shushan D, Breuer A, Zolotarev O, Okon A, Fink N, Katz V, Berry EM. (2004). Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacol Biochem Behav. 2004 Apr;77(4):675-84. doi: 10.1016/j.pbb.2004.01.015. https://pubmed.ncbi.nlm.nih.gov/15099912/

Bar-Sela, Vorobeichik, Drawshesh, Omer, Goldberg, and Muller. 2013. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evidence-Based Complementary and Alternative Medicine, volume 2013. https://pubmed.ncbi.nlm.nih.gov/23956774/

Bleckwenn M, Weckbecker K, Voss S. (2018). Beneficial effect of medical cannabis in the treatment of a pharmacoresistant nausea associated with a somatoform disorder in a patient with post-polio syndrome. Dtsch Med Wochenschr. 2018 Mar;143(5):344-348. https://pubmed.ncbi.nlm.nih.gov/29506301/

Brents, L. (2016). Marijuana, the endocannabinoid system and the female reproductive system. Yale J Biol Med. 2016 Jun; 89(2): 175–191. https://pubmed.ncbi.nlm.nih.gov/27354844/

Buracchio, T. (2018). Peripheral and Central Nervous System Drugs Advisory Committee Meeting. FDA Briefing Document NDA 210365. https://www.fda.gov/media/112565/download

Cahn RS (1932) Cannabis indica resin, Part III. The constitution of Cannabinol. Jrnl of the Chemical Society, 1342–1353. https://pubs.rsc.org/en/content/articlelanding/1932/jr/jr9320001342#!divAbstract

Carter, Abood, Aggarwal, and Weiss. 2010. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. American Journal of Hospice & Palliative Medicine, 27(5), 347-356. https://pubmed.ncbi.nlm.nih.gov/20439484/

Collin C, Davies P, Mutiboko IK, Ratcliffe S. (2007). Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology, 23 February 2007. https://pubmed.ncbi.nlm.nih.gov/17355549/

Crombie L, Ponsford R (1968) Hashish components. Photochemical production of cannabicyclol from cannabichromene. Tetrahedron Lett 9: 5771–5772. https://pubmed.ncbi.nlm.nih.gov/5697175/

Currais A, Quehenberger O, Armando A, Daugherty D, Maher P, Schubert, D. (2016). Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. Npj Aging And Mechanisms Of Disease, Volume 2. https://www.nature.com/articles/npjamd201612

Cuttler C, Spradlin A, McLaughlin RJ. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord. 2018 Aug 1;235:198-205. doi: 10.1016/j.jad.2018.04.054. Epub 2018 Apr 6. https://pubmed.ncbi.nlm.nih.gov/29656267/

Deadwyler S, et al. (1997). Marijuana & analgesia. Press Conference, Society for Neuroscience 27th Annual Meeting, New Orleans. October 26, 1997. https://www.compassionatecertificationcenters.com/wp-content/uploads/2016/09/CCC_Patients_Guide_to_Medical_Cannabis.pdf

Devane WV, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 18 Dec 1992: Vol. 258, Issue 5090, 1946-1949. https://pubmed.ncbi.nlm.nih.gov/1470919/

Di Marzo V, Breivogel C, Tao Q, Bridgen D, Razdan RK, Zimmer AM, Zimmer A, Martin BR. (2008). Levels, metabolism, and pharmacological activity of anandamide in cb1 cannabinoid receptor knockout mice. Journal of Neurochemistry, Volume 75, Issue 6. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1471-4159.2000.0752434.x

Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, Beeri R, Pugatsch T, Tarsish E, Lotan C. (2007). Cannabidiol, a nonpsychoactive cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3602-7. Epub 2007 Sep 21. https://pubmed.ncbi.nlm.nih.gov/17890433/

Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. (2018). Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front. Immunol., 03 August 2018 | https://doi.org/10.3389/fimmu.2018.01782

Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. Sci. 86: 1646. https://pubs.acs.org/doi/10.1021/ja01062a046

Gaoni Y and Mechoulam R (1966) Cannabichromene, a new active principle in hashish. Chem Commun 20–21. https://pubs.rsc.org/en/content/articlelanding/1966/c1/c19660000020#!divAbstract

Green A, De-Vries K. (2010). Cannabis use in palliative care - an examination of the evidence and the implications for nurses, Journal of Clinical Nursing, 2010, 19, 2454-2462. https://pubmed.ncbi.nlm.nih.gov/20920073/

Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016 Jul; 20(6): 936–948. Published online 2015 Oct 30. doi: 10.1002/ejp.818 | https://pubmed.ncbi.nlm.nih.gov/26517407/

Harrar, S. (2019). What Medical Marijuana Works For. AARP, Published online at https://www.aarp.org/health/drugs-supplements/info-2019/cannabis-for-medical-conditions.html.

Howlett AC, Johnson MR, Melvin LS and Milne GM (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Molecular Pharmacology March 1988, 33 (3) 297-302. https://pubmed.ncbi.nlm.nih.gov/3352594/

Jacob A and Todd AR (1940) Cannabis Indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. Journal of the Chemical Society. 649. https://pubs.rsc.org/en/content/articlelanding/1940/JR/jr9400000649#!divAbstract

Joy JE, Watson SJ Jr., Benson JA Jr. (1999). *Marijuana and Medicine: Assessing the Science Base*. Chapter 4: The medical value of marijuana and related substances. Institute of Medicine (US); Washington (DC): Natl Acad Press (US); 1999. https://www.nap.edu/catalog/6376/marijuana-and-medicine-assessing-the-science-base

Kirkham TC. (2005). Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. 2005 Sep; 16(5-6):297-313. https://pubmed.ncbi.nlm.nih.gov/16148436/

Kirkham TC. (2009). Cannabinoids and appetite: food craving and food pleasure . Int Rev Psych. 2009 Apr;21(2):163-71. https://pubmed.ncbi.nlm.nih.gov/19367510/

Kohno M1, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa M. (2006). Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun. 2006 Sep 1;347(3):827-32. Epub 2006 Jul 10. https://pubmed.ncbi.nlm.nih.gov/16844083/

Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. (2014). Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29; 82(17): 1556–1563. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011465/

Li HL (1974) An archaeological and historical account of cannabis in China. Econ Bot 28: 437–448. https://www.jstor.org/stable/4253540?seq=1

Li Q, Wang F, Zhang YM, Zhou JJ, Zhang Y. (2013). Activation of cannabinoid type 2 receptor by jwh133 protects heart against ischemia/reperfusion-induced apoptosis. Cell Physiol Biochem 2013;31:693-702. https://pubmed.ncbi.nlm.nih.gov/23711495/

Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. PNAS August 15, 2000. 97 (17) 9561-9566. https://www.pnas.org/content/97/17/9561

Manzanares J, Julian MD, Carrascosa A. (2006). Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006 Jul; 4(3): 239–257. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430692/

Marichal-Cancinoa BA, Fajardo-Valdeza A, Ruiz-Contreras AE, Méndez-Díaza M, Prospéro-Garcíaa O. (2017). Advances in the physiology of GPR55 in the central nervous system. Curr Neuropharmacol. 2017 Jul; 15(5): 771–778. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771053/

McAllister SD, Soroceanu L, Desprez PY. (2015). The Antitumor Activity of Plant-Derived Non-Psychoactive cannabinoids. Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. https://pubmed.ncbi.nlm.nih.gov/25916739/

McCarthy, Justin (2018) Two in three Americans now support legalizing marijuana. https://news.gallup.com/poll/243908/two-three-americans-support-legalizing-marijuana.aspx

McHugh, D. (1012). GPR18 in microglia: implications for the CNS and endocannabinoid system signaling. Br J Pharmacol. 2012 Dec; 167(8): 1575–1582. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525861/

McPartland J, Di Marzo V, De Petrocellis L, Mercer A, Glass M (2001). Cannabinoid receptors are absent in insects. Journal of Comparative Neurology 6;426(4):423-9. https://pubmed.ncbi.nlm.nih.gov/11447587/

McPartland J, Norris R, Kilpatrick W. (2007). Coevolution between cannabinoid receptors and endocannabinoid ligands. Gene Volume 397, Issues 1–2, 1 August 2007, Pages 126-135. https://pubmed.ncbi.nlm.nih.gov/17537592/

Mechoulam R and Gaoni Y (1965). Hashish—IV: The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron 21: 1223–1229. https://www.sciencedirect.com/science/article/abs/pii/0040402065800643

Mechoulam R and Hanus L (2000) A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids. Volume 108, Issues 1–2, 1-13. https://pubmed.ncbi.nlm.nih.gov/11106779/

Mechoulam R, Ben-Zvi Z, Yagnitinsky B, Shani A (1969) A new tetrahydrocannabinolic acid. Tetrahedron Lett 10: 2339–2341. https://www.sciencedirect.com/science/article/abs/pii/S0040403901881582

Mechoulam R, Hanus L, Martin BR (1994) Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol. 1994 Oct 18;48(8): 1537–1544. https://pubmed.ncbi.nlm.nih.gov/7980618/

Mechoulam R, Shvo Y (1964) Hashish. I. The structure of cannabidiol. Tetrahedron. 19: 2073. https://pubmed.ncbi.nlm.nih.gov/5879214/

Metz L, Page S (2003). Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet, 362(9395):1513. https://pubmed.ncbi.nlm.nih.gov/14615102/

Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo FM, Offertaler L, Pacher P, Kunos G, Mechoulam R. (2006). N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties. PNAS February 14, 2006. 103 (7) 2428-2433. https://pubmed.ncbi.nlm.nih.gov/16467152/

Munro S, Thomas KL & Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65. https://www.nature.com/articles/365061a0

Munson AE, Harris LS, Friedman MA, Dewey WL, and Carchman RA. (1975). Antineoplastic activity of cannabinoids. Natl Cancer Inst . 1975 Sep;55(3):597-602. doi: 10.1093/jnci/55.3.597. https://pubmed.ncbi.nlm.nih.gov/1159836/

Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001 Oct 4;413(6855):527-31. https://pubmed.ncbi.nlm.nih.gov/11586361/

Philpott HT, O'Brien M, and McDougall JJ. (2017). Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017 Dec; 158(12): 2442–2451. Published online 2017 Sep 1. https://pubmed.ncbi.nlm.nih.gov/28885454/

Pillarisetti S, Alexander CW, Khanna I. (2009). Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discovery Today, Volume 14, Issues 23–24, December 2009, Pages 1098-1111. https://www.semanticscholar.org/paper/Pain-and-beyond%3A-fatty-acid-amides-and-fatty-acid-Pillarisetti-Alexander/b8ff6ac32e43af19feee73dc05b051a8ad78ab53

Rahn, EJ and Hohmann AG. (2009). Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics. 2009 Oct; 6(4): 713–737. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755639/

Riggs PK et al. (2012). A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 2012 Jan 11;1431:46-52. https://pubmed.ncbi.nlm.nih.gov/22133305/

Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirlin KA. (2002). Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. Journal of Cannabis Therapeutics, Volume 2, 2002 - Issue 1.

Russo, EB. (2008). Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008 Feb; 4(1): 245–259. doi: 10.2147/tcrm.s1928 | https://www.cannabis-med.org/jcant/russo_chronic_use.pdf

Russo, EB. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other. Cannabis and Cannabinoid Research, Volume 1.1:154-165. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/

Samuelson LC, Swanberg LJ, Gantz I. (2006). Mapping of the novel G protein-coupled receptor Gprl8 to distal mouse chromosome 14. Mammalian Genome. December 1996, Volume 7, Issue 12, 920–921. https://pubmed.ncbi.nlm.nih.gov/8995768/

Sansone RA, Sansone, LA. (2014). Marijuana and body weight. Innov Clin Neurosci. 2014 Jul-Aug; 11(7-8): 50–54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204468/

Sexton, M; Cutlier, C; Mischeley, L. (2019). A survey of cannabis acute effects and withdrawal symptoms: differential responses across user types and age. J Altern Complement Med. 2019 Mar 1; 25(3): 326–335. https://pubmed.ncbi.nlm.nih.gov/30383388/

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of ALS when initiated at symptom onset. J Neurochem 2007;101(1):87098. https://pubmed.ncbi.nlm.nih.gov/17241118/

Stanley S, O'Sullivan SE. (2014). Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol. 2014 Mar; 171(6): 1361–1378. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954478/

Stith, S et al. (2018). Patient-reported symptom relief following medical cannabis consumption front. Pharmacol., 28 August 2018. https://www.frontiersin.org/articles/10.3389/fphar.2018.00916/full

Sultan SR, Millar SA, O'Sullivan SE, and England TH. (2018) A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ^8-Tetrahydrocannabinol. Pharmaceuticals (Basel) . 2018 Jan 31;11(1):13. doi: 10.3390/ph11010013. https://pubmed.ncbi.nlm.nih.gov/29385080/

Takeda S, Okazaki H, Ikeda E, Abe S, Yoshioka Y, Watanabe K, Aramaki H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. J Toxicol Sci. 2014;39(5):711-6. https://pubmed.ncbi.nlm.nih.gov/25242400/

Thapa D, Cairns EA, Szczesniak AM, Toguri JT, Caldwell MD, and Kelly MEM. (2018). The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation. Cannabis Cannabinoid Res. 2018; 3(1): 11–20. Published online 2018 Feb 1. doi: 10.1089/can.2017.0041 PMCID: PMC5812319 PMID: 29450258. https://pubmed.ncbi.nlm.nih.gov/29450258/

Tomida I, Pertwee RG, Azuara-Blanco A. (2004). Cannabinoids and glaucoma. Br J Ophthalmol. 2004 May; 88(5): 708–713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772142/

Tramèr MR, Carroll D, Campbell FA, Reynolds JM, Moore RA, McQuay HJ. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001 Jul 7; 323(7303): 16. https://pubmed.ncbi.nlm.nih.gov/11440936/

Vidrio H, Sánchez-Salvatori MA, Medina M. (1996). Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. Cardiovasc Pharmacol . 1996 Aug;28(2):332-6. doi: 10.1097/00005344-199608000-00022. https://pubmed.ncbi.nlm.nih.gov/8856492/

Viswambharan V, Manepalli IN, Grossberg GT. (2013). Orexigenic agents in geriatric clinical practice. Health 9(1):49-65. https://www.researchgate.net/publication/271061935_Orexigenic_agents_in_geriatric_clinical_practice

Wade DT et al. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434-41. https://pubmed.ncbi.nlm.nih.gov/15327042/

Wade DT, Robson P, House H, Makela P. (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. J.Clin Rehabil. 2003 Feb;17(1):21-9. https://pubmed.ncbi.nlm.nih.gov/12617376/

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. (2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010 Oct 5; 182(14): E694–E701. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950205/

Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008 Jan; 54(1): 244–249. https://pubmed.ncbi.nlm.nih.gov/17714746/

Wiese B, Wilson-Poe AR. (2018) Emerging evidence for cannabis' role in opioid use disorder. Cannabis and Cannabinoid Research 3:1, 179–189. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135562/

Wood TB, Spivey WTN, Easterfield TH (1899) Cannabinol. Part I. J Chem Soc 75: 20–36. https://pubs.rsc.org/en/content/articlelanding/1899/ct/ct8997500020#!divAbstract

Woolridge, MB et al. (2005). Cannabis use in HIV for pain and other medical symptoms. April 2005, Volume 29, Issue 4, Pages 358–367. https://www.jpsmjournal.com/article/S0885-3924(05)00063-1/fulltext

Yamauchi T, Shoyama Y, Aramaki H, Azuma T, Nishioka I (1967) Tetrahydrocannabinolic acid a genuine substance of tetrahydrocannabinol. Chem Pharm Bull 15, 1075. https://pubmed.ncbi.nlm.nih.gov/5583149/

Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. PNAS May 11, 1999. 96 (10) 5780-5785. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC21937/